Wegovy Pill Takes Early Lead
1:44–2:24 · 40s
Peter Loftus says Novo Nordisk has the edge in the pill-versus-pill battle, citing a record-fast launch, over a million patients since January, and stronger trial efficacy versus Lilly’s Fontnio.
1:44–2:24 · 40s
Peter Loftus says Novo Nordisk has the edge in the pill-versus-pill battle, citing a record-fast launch, over a million patients since January, and stronger trial efficacy versus Lilly’s Fontnio.
We use cookies to understand how you use our platform and to improve your experience. Click "Accept All" to consent, or "Decline non-essential" to opt out of non-essential cookies. Read our Privacy Policy.